From May 11 to 13, 2026, the Hospital Authority Annual Convention 2026, organized by the Hospital Authority of Hong Kong, was successfully held at the Hong Kong Convention and Exhibition Centre. As a marquee event of the Hong Kong International Medical and Healthcare Week, the convention adhered to the HA's core values of "People First, Professional Commitment, Dedicated Service, and Teamwork." It featured 75 thematic sessions and attracted over 9,000 medical experts and scholars from home and abroad. Participants engaged in in-depth discussions and extensive exchanges on major topics including sustainable development of healthcare systems, comprehensive prevention and control of chronic diseases, cancer prevention and treatment strategies, artificial intelligence applications in medicine, and responses to population aging, exploring new pathways for global healthcare development.

Shenzhen Cell Valley was invited to attend the convention and shared cutting-edge insights at a thematic session titled "Advances in Cell and Gene Therapy Under the Current Regulatory Framework." Qiu Dagen Legislative Council Member for the Technology and Innovation Constituency of the Hong Kong Special Administrative Region, with many distinguished medical experts and scholars at home and abroad including those from Hong Kong Biotechnology Research Institute and the Hospital Authority of Hong Kong in attendance.

Dr. Fu Yuchen, Assistant to the Chairman and Director of the International Medical Service Center at Shenzhen Cell Valley, attended the convention on behalf of Chairman Professor Shi Yuanyuan and delivered an English-language presentation entitled "The Complex and Evolving Issues on Cell and Gene Therapy Regulatory Framework." Fu Yuchen highlighted the hospital-led innovation translation pathway under China's Decree No. 818 framework and introduced in detail the "Shenzhen Model" and "Shenyang Model" developed by Shenzhen Cell Valley in collaboration with government partners. Through a dual-wheel drive mechanism, the two models jointly establish a complete ecosystem integrating "six-dimensional infrastructure" and an H2I (Hospital to Industry) translation platform, achieving an efficient closed loop from technology R&D to clinical translation. This validated practical model has already provided a replicable and scalable standardization paradigm for cell and gene therapy industry platforms in China and across the Asia-Pacific region.

During the symposium, participants engaged in in-depth discussions on core issues including cross-border clinical research, cost revolution, and regulatory coordination. All parties agreed that Shenzhen and Hong Kong should fully leverage their respective strengths, deepen collaboration, accelerate the clinical translation and application of advanced therapies, and jointly promote Hong Kong as an international benchmark for the translation and application of cell and gene therapy in the Asia-Pacific region.